Adaptimmune Therapeutics Plc (ADAP) — Cash Flow Reinvestment Rate
Adaptimmune Therapeutics Plc (ADAP) has a Cash Flow Reinvestment Rate of 0.03x as of June 2024, reinvesting $1.50 Million (capex $754.55K plus investments $-743.00K) from operating cash flow of $47.39 Million. Check ADAP cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Adaptimmune Therapeutics Plc Cash Flow Reinvestment Rate (2013–2021)
Historical reinvestment intensity for Adaptimmune Therapeutics Plc across 2 annual periods. Explore debt repayment capacity of Adaptimmune Therapeutics Plc to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for Adaptimmune Therapeutics Plc (2013–2021)
Year-by-year capital reinvestment analysis for Adaptimmune Therapeutics Plc. For live market cap and broader valuation context, see ADAP stock market capitalisation.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2021 | 8.70x | $93.36 Million | $10.73 Million | $8.78 Million | ▲ +485.6% |
| 2013 | 1.49x | $55.33 Million | $37.23 Million | $1.45 Million | — |